AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

This growth is driven by the increasing shift toward home-based healthcare and the rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma.

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Sharada Gudur, a Respiratory Medicine Consultant at Lancashire Teaching Hospitals and a respiratory champion for Lancashire and South Cumbria Integrated Care Board, recently joined representatives ...

What are the symptoms of emphysema? - Understanding the condition is the first step towards taking control of your lung ...